These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 35124261)

  • 21. Six-month humoral and cellular immune response to the third dose of BNT162b2 anti-SARS-CoV-2 vaccine in patients with solid tumors: a longitudinal cohort study with a focus on the variants of concern.
    Lasagna A; Bergami F; Lilleri D; Percivalle E; Quaccini M; Serra F; Comolli G; Sarasini A; Sammartino JC; Ferrari A; Arena F; Secondino S; Cicognini D; Schiavo R; Lo Cascio G; Cavanna L; Baldanti F; Pedrazzoli P; Cassaniti I
    ESMO Open; 2022 Oct; 7(5):100574. PubMed ID: 36029652
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Kinetics of vaccine-induced neutralizing antibody titers and estimated protective immunity against wild-type SARS-CoV-2 and the Delta variant: A prospective nationwide cohort study comparing three COVID-19 vaccination protocols in South Korea.
    Nham E; Ko JH; Song KH; Choi JY; Kim ES; Kim HJ; Kim B; Lim HY; Kim KC; Jang HC; Lee KH; Song YG; Baek YJ; Ahn JY; Choi JY; Kim YC; Park YS; Choi WS; Bae S; Kim SH; Kang ES; Jeong HW; Kim SW; Kwon KT; Kim SS; Peck KR
    Front Immunol; 2022; 13():968105. PubMed ID: 36211416
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immune Responses Against SARS-CoV-2 WT and Delta Variant in Elderly BNT162b2 Vaccinees.
    Jäger M; Sonnleitner ST; Dichtl S; Lafon E; Diem G; Walder G; Lass-Flörl C; Wilflingseder D; Posch W
    Front Immunol; 2022; 13():868361. PubMed ID: 35833113
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neutralization of SARS-CoV-2 Variants of Concern in Kidney Transplant Recipients after Standard COVID-19 Vaccination.
    Benning L; Morath C; Bartenschlager M; Nusshag C; Kälble F; Buylaert M; Schaier M; Beimler J; Klein K; Grenz J; Reichel P; Hidmark A; Ponath G; Töllner M; Reineke M; Rieger S; Tönshoff B; Schnitzler P; Zeier M; Süsal C; Bartenschlager R; Speer C
    Clin J Am Soc Nephrol; 2022 Jan; 17(1):98-106. PubMed ID: 34937771
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antibody Avidity Maturation Following Recovery From Infection or the Booster Vaccination Grants Breadth of SARS-CoV-2 Neutralizing Capacity.
    Nakagama Y; Candray K; Kaku N; Komase Y; Rodriguez-Funes MV; Dominguez R; Tsuchida T; Kunishima H; Nagai E; Adachi E; Ngoyi DM; Yamasue M; Komiya K; Hiramatsu K; Uemura N; Sugiura Y; Yasugi M; Yamagishi Y; Mikamo H; Shiraishi S; Izumo T; Nakagama S; Watanabe C; Nitahara Y; Tshibangu-Kabamba E; Kakeya H; Kido Y
    J Infect Dis; 2023 Mar; 227(6):780-787. PubMed ID: 36546706
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Potency of BNT162b2 and mRNA-1273 vaccine-induced neutralizing antibodies against severe acute respiratory syndrome-CoV-2 variants of concern: A systematic review of in vitro studies.
    Noori M; Nejadghaderi SA; Arshi S; Carson-Chahhoud K; Ansarin K; Kolahi AA; Safiri S
    Rev Med Virol; 2022 Mar; 32(2):e2277. PubMed ID: 34286893
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antibody titers against the Alpha, Beta, Gamma, and Delta variants of SARS-CoV-2 induced by BNT162b2 vaccination measured using automated chemiluminescent enzyme immunoassay.
    Kato H; Miyakawa K; Ohtake N; Go H; Yamaoka Y; Yajima S; Shimada T; Goto A; Nakajima H; Ryo A
    J Infect Chemother; 2022 Feb; 28(2):273-278. PubMed ID: 34857462
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Serum neutralization of SARS coronavirus 2 Omicron sublineages BA.1 and BA.2 and cellular immune responses 3 months after booster vaccination.
    Alidjinou EK; Demaret J; Corroyer-Simovic B; Vuotto F; Miczek S; Labreuche J; Goffard A; Trauet J; Lupau D; Dendooven A; Huvent-Grelle D; Podvin J; Dreuil D; Faure K; Deplanque D; Bocket L; Duhamel A; Sobaszek A; Hober D; Hisbergues M; Puisieux F; Autran B; Yazdanpanah Y; Labalette M; Lefèvre G
    Clin Microbiol Infect; 2023 Feb; 29(2):258.e1-258.e4. PubMed ID: 36257549
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Neutralizing Response Against SARS-CoV-2 Variants 8 Months After BNT162b2 Vaccination in Naive and COVID-19-Convalescent Individuals.
    Luczkowiak J; Labiod N; Rivas G; Rolo M; Lasala F; Lora-Tamayo J; Mancheno-Losa M; Rial-Crestelo D; Pérez-Rivilla A; Folgueira MD; Delgado R
    J Infect Dis; 2022 Jun; 225(11):1905-1908. PubMed ID: 34963008
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Factors associated with anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein antibody titer and neutralizing activity among healthcare workers following vaccination with the BNT162b2 vaccine.
    Kobashi Y; Shimazu Y; Kawamura T; Nishikawa Y; Omata F; Kaneko Y; Kodama T; Tsubokura M
    PLoS One; 2022; 17(6):e0269917. PubMed ID: 35687563
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Decreased Efficiency of Neutralizing Antibodies from Previously Infected or Vaccinated Individuals against the B.1.617.2 (Delta) SARS-CoV-2 Variant.
    Dimeglio C; Herin F; Da-Silva I; Gernigon C; Porcheron M; Chapuy-Regaud S; Izopet J
    Microbiol Spectr; 2022 Aug; 10(4):e0270621. PubMed ID: 35867411
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effectiveness of the third dose of BNT162b2 vaccine on neutralizing Omicron variant in the Japanese population.
    Kawasuji H; Morinaga Y; Tani H; Saga Y; Kaneda M; Murai Y; Ueno A; Miyajima Y; Fukui Y; Nagaoka K; Ono C; Matsuura Y; Niimi H; Yamamoto Y
    J Infect Chemother; 2022 Sep; 28(9):1273-1278. PubMed ID: 35691864
    [TBL] [Abstract][Full Text] [Related]  

  • 33. B-cell responses to vaccination with BNT162b2 and mRNA-1273 6 months after second dose.
    Markewitz R; Pauli D; Dargvainiene J; Steinhagen K; Engel S; Herbst V; Zapf D; Krüger C; Sharifzadeh S; Schomburg B; Leypoldt F; Rupp J; Görg S; Junker R; Wandinger KP
    Clin Microbiol Infect; 2022 Jul; 28(7):1024.e1-1024.e6. PubMed ID: 35259531
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Heterologous ChAdOx1 and Bnt162b2 vaccination induces strong neutralizing antibody responses against SARS-CoV-2 including delta variant with tolerable reactogenicity.
    Bae S; Ko JH; Choi JY; Park WJ; Lim SY; Ahn JY; Song KH; Lee KH; Song YG; Chan Kim Y; Park YS; Choi WS; Jeong HW; Kim SW; Kwon KT; Kang ES; Kim AR; Jang S; Kim B; Kim SS; Jang HC; Choi JY; Kim SH; Peck KR
    Clin Microbiol Infect; 2022 Oct; 28(10):1390.e1-1390.e7. PubMed ID: 35598855
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The role of neutralizing antibodies by sVNT after two doses of BNT162b2 mRNA vaccine in a cohort of Italian healthcare workers.
    Infantino M; Manfredi M; Stacchini L; Cosma C; Grossi V; Lari B; Russo E; Amedei A; Benucci M; Veneziani F; Casprini P; Catalano CM; Cirrincione G; Bonaccorsi G; Pompetti A
    Clin Chem Lab Med; 2022 May; 60(6):934-940. PubMed ID: 35303766
    [TBL] [Abstract][Full Text] [Related]  

  • 36. SARS-CoV-2 Gamma and Delta Variants of Concern Might Undermine Neutralizing Activity Generated in Response to BNT162b2 mRNA Vaccination.
    Trabace L; Pace L; Morgese MG; Santo IB; Galante D; Schiavone S; Cipolletta D; Rosa AM; Reveglia P; Parisi A; Tucci P; Pepe G; Sacco R; Foschino Barbaro MP; Corso G; Fasanella A
    Viruses; 2022 Apr; 14(4):. PubMed ID: 35458544
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A cohort analysis of SARS-CoV-2 anti-spike protein receptor binding domain (RBD) IgG levels and neutralizing antibodies in fully vaccinated healthcare workers.
    Padoan A; Cosma C; Della Rocca F; Barbaro F; Santarossa C; Dall'Olmo L; Galla L; Cattelan A; Cianci V; Basso D; Plebani M
    Clin Chem Lab Med; 2022 Jun; 60(7):1110-1115. PubMed ID: 35473824
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fourth BNT162b2 vaccination neutralization of omicron infection after heart transplantation.
    Peled Y; Afek A; Nemet I; Rahav G; Raanani E; Patel JK; Mandelboim M
    J Heart Lung Transplant; 2022 Sep; 41(9):1210-1213. PubMed ID: 35794051
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of Antibody Response Elicited by ChAdOx1 and BNT162b2 COVID-19 Vaccine.
    Kang YM; Minn D; Lim J; Lee KD; Jo DH; Choe KW; Kim MJ; Kim JM; Kim KN
    J Korean Med Sci; 2021 Nov; 36(46):e311. PubMed ID: 34845875
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The temporal course of T- and B-cell responses to vaccination with BNT162b2 and mRNA-1273.
    Markewitz R; Pauli D; Dargvainiene J; Steinhagen K; Engel S; Herbst V; Zapf D; Krüger C; Sharifzadeh S; Schomburg B; Leypoldt F; Rupp J; Görg S; Junker R; Wandinger KP
    Clin Microbiol Infect; 2022 May; 28(5):701-709. PubMed ID: 34547457
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.